Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05654675Recruiting
Scan method study for measuring tumor sugar use on PET
This study checks whether a specific analysis method (called FUR) can better measure how much “sugar” from PET scans is used by tumors. It uses regular PET/CT scans you may already get as part of standard care, and compares how the measurements work.
Maastricht, LimburgAges 18 years+ - NCT05657847Recruiting
Imaging tests for joint disease in arthritis
This study tests new kinds of imaging (radiology pictures) to help understand arthritis in joints. It may help improve how these arthritis types are identified and followed over time.
BudapestAges 18–100 - NCT05657652Recruiting
Medicine regimen for relapsed or refractory B-ALL
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
Suzhou, JiangsuAges 15–70 - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05659732RecruitingPhase 1
Testing a new drug for advanced blood cancers
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
Clayton, VictoriaAges 18 years+ - NCT05660148Recruiting
HIV study on resentment, forgiveness, and quality of life
This study looks at how feelings like resentment and the ability to forgive relate to quality of life in people living with HIV. You may be asked to participate in questionnaires and/or follow-up that can be done by phone or video.
AmiensAges 18 years+ - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT05663580Recruiting
Study of HIV treatment with long-acting injected medicines
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
MilanAges 18 years+ - NCT05667610Recruiting
Immune and gut diet study for peanut-allergic children
This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.
AmsterdamAges 3–17 - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT05669534RecruitingPhase 4
HIV prevention support for people starting PrEP
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
New Haven, ConnecticutAges 18 years+ - NCT05670301Recruiting
Blood test study to profile inflammation biomarkers in diseases
This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.
AntwerpAges Any age - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Baltimore, MarylandAges 18–65 - NCT05671718Recruiting
Nurse vs doctor treatment for drug-resistant tuberculosis
This trial compares a nurse-led plan versus a physician-led plan for treating new drug-resistant TB patients using an outpatient clinic approach. It may help by showing which care style works best and is safest for patients starting treatment close to home.
Pietermaritzburg, KwaZulu-NatalAges 18 years+ - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT05674695Recruiting
Registry study for starting or switching atopic eczema medicines
This study follows people with atopic eczema when they start or switch to a specific medicine that affects the immune system. It helps doctors understand how these treatments work in real life, including for skin symptoms and daily quality of life.
Badalona, BarcelonaAges Any age - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT05675813RecruitingPhase 1/Phase 2
Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05675930RecruitingPhase 2
Light therapy for mouth GVHD after a stem cell transplant
This Phase 2 study tests a special light treatment (photobiomodulation) to improve oral graft-versus-host disease (GVHD) after a stem cell transplant. It may help people whose mouth symptoms have not improved with at least one prior treatment.
Bethesda, MarylandAges 4 years+ - NCT05676099Recruiting
TSC or LAM blood and health information registry
This study sets up a database and collection of “biosamples” (like blood or other body samples) from people with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). The goal is to better understand how these conditions change over time and support future research.
Birmingham, AlabamaAges Any age - NCT05676450Recruiting
Test blood DNA to find lymphoma changes and leftover disease
This study checks a blood test that looks for small DNA fragments (“cell-free DNA”) to find cancer changes that could guide treatment in diffuse large B-cell lymphoma. It also looks for “minimal residual disease,” meaning tiny amounts of lymphoma that may remain after treatment, and whether this test works across community cancer centers in Texas.
Houston, TexasAges 18 years+ - NCT05678374Recruiting
Looking for immune signs linked to mental fatigue in Graves’ disease
This study looks at blood “immune” markers to understand why some people with Graves’ disease develop mental fatigue (feeling slowed down in thinking). It may help doctors better recognize and explain mental fatigue in Graves’ disease.
GothenburgAges 18–72
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.